¿ AltaRex Corp., of Waltham, Mass., said it will implement a 1-for-4 share consolidation approved by shareholders in May. The consolidation will reduce the shares outstanding from 74 million to 18.5 million. AltaRex said the move is in preparation for financing measures to fund the regulatory approval process for its OvaRex monoclonal antibody, which the company plans to seek approval for by the end of 2001.

No Comments